3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Gynecologic
4
Breast
3
Thoracic
1
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Dermatologic
1
Conditions
Lung Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Small Cell Lung Carcinoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Liver Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Brain Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
pembrolizumab
42
Carboplatin
24
Cyclophosphamide
20
Paclitaxel
19
Nivolumab
17
Cisplatin
15
fludarabine
14
Gemcitabine
12
aldesleukin
10
Docetaxel
10
Bevacizumab
9
Magnetic Resonance Spectroscopy
8
Trastuzumab
7
Specimen Handling
7
Drug Therapy
7
Pemetrexed
6
Oxaliplatin
6
Ipilimumab
6
Interleukin-2
6
Fluorouracil
6
Cetuximab
6
Blood Specimen Collection
6
sargramostim
5
pegfilgrastim
5
avelumab
5
Topotecan
5
Taxes
5
Irinotecan
5
palbociclib
4
durvalumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Mass Spectrometry
×
Thoracic
×
Clear all
NCT00900094
2012-02-07
IRB 2000-294
University of Michigan Rogel Cancer Center
Completed
200 enrolled